HIV self-testing in Ottawa, Canada used by persons at risk for HIV: The GetaKit study.
Canada
GetaKit
Keywords: HIV
Ottawa
priority group
self-test
Journal
Canada communicable disease report = Releve des maladies transmissibles au Canada
ISSN: 1188-4169
Titre abrégé: Can Commun Dis Rep
Pays: Canada
ID NLM: 9303729
Informations de publication
Date de publication:
14 Oct 2021
14 Oct 2021
Historique:
entrez:
5
11
2021
pubmed:
6
11
2021
medline:
6
11
2021
Statut:
epublish
Résumé
The Public Health Agency of Canada estimates that about 87% of persons living with human immunodeficiency virus (HIV) in Canada have been diagnosed, which is well below the Joint United Nations Programme on HIV/AIDS target to have 95% of HIV-positive persons diagnosed. Research has shown that HIV self-testing may help increase such diagnoses, especially among the populations who are most affected by HIV. The objective of the study was to determine the uptake and diagnosis outcomes associated with free HIV self-testing. We developed the first online mailout free HIV self-testing program in Canada and implemented it in Ottawa. This project ran through the website, www.GetaKit.ca. We intended to recruit 150-400 participants over a 6-12-month period, estimating that this number would yield between 0-1 positive test results (expected positivity rate of 0.08%). Between July 20, 2020 and April 1, 2021, 1,268 people accessed the GetaKit website and verified their eligibility. In total, 600 persons were eligible and 405 ordered an HIV kit. Of those who ordered a kit, 399 completed a baseline survey. Overall, 71% of these participants were members of HIV priority groups. For test results, 228 persons reported test results, with one being positive, for a positivity rate of 0.24% overall and 0.44% of reported results. These rates exceed that normally observed in Ottawa. Self-testing of HIV can be effectively delivered through a website. Such an intervention will also be used by persons with undiagnosed infections and appears to do so at a rate higher than that observed by other means of testing. Self-testing of HIV may therefore help Canada achieve the United Nations 95-95-95 targets.
Sections du résumé
BACKGROUND
BACKGROUND
The Public Health Agency of Canada estimates that about 87% of persons living with human immunodeficiency virus (HIV) in Canada have been diagnosed, which is well below the Joint United Nations Programme on HIV/AIDS target to have 95% of HIV-positive persons diagnosed. Research has shown that HIV self-testing may help increase such diagnoses, especially among the populations who are most affected by HIV. The objective of the study was to determine the uptake and diagnosis outcomes associated with free HIV self-testing.
METHODS
METHODS
We developed the first online mailout free HIV self-testing program in Canada and implemented it in Ottawa. This project ran through the website, www.GetaKit.ca. We intended to recruit 150-400 participants over a 6-12-month period, estimating that this number would yield between 0-1 positive test results (expected positivity rate of 0.08%).
RESULTS
RESULTS
Between July 20, 2020 and April 1, 2021, 1,268 people accessed the GetaKit website and verified their eligibility. In total, 600 persons were eligible and 405 ordered an HIV kit. Of those who ordered a kit, 399 completed a baseline survey. Overall, 71% of these participants were members of HIV priority groups. For test results, 228 persons reported test results, with one being positive, for a positivity rate of 0.24% overall and 0.44% of reported results. These rates exceed that normally observed in Ottawa.
CONCLUSION
CONCLUSIONS
Self-testing of HIV can be effectively delivered through a website. Such an intervention will also be used by persons with undiagnosed infections and appears to do so at a rate higher than that observed by other means of testing. Self-testing of HIV may therefore help Canada achieve the United Nations 95-95-95 targets.
Identifiants
pubmed: 34737676
doi: 10.14745/ccdr.v47i10a06
pii: 471006
pmc: PMC8525857
doi:
Types de publication
Journal Article
Langues
eng
Pagination
435-441Déclaration de conflit d'intérêts
Competing interests: None.
Références
Influenza Other Respir Viruses. 2018 Nov;12(6):808-813
pubmed: 30028081
Sci Rep. 2021 May 26;11(1):11025
pubmed: 34040014
Int J Environ Res Public Health. 2020 Oct 27;17(21):
pubmed: 33121070
Hum Vaccin Immunother. 2021 Jul 3;17(7):2169-2175
pubmed: 33377817
JAMA. 2020 May 26;323(20):2085-2086
pubmed: 32293646
Euro Surveill. 2020 Feb;25(7):
pubmed: 32098644
Int J Epidemiol. 2021 Aug 30;50(4):1124-1133
pubmed: 33942104
Influenza Other Respir Viruses. 2021 Nov;15(6):697-700
pubmed: 34169670
PLoS Med. 2010 Apr 06;7(4):e1000258
pubmed: 20386731
Vaccine. 2020 Jan 10;38(2):350-354
pubmed: 31607599
Clin Infect Dis. 2020 Nov 19;71(16):2285-2288
pubmed: 32442261
Sci Rep. 2021 Feb 26;11(1):4741
pubmed: 33637783
BMC Infect Dis. 2015 Oct 17;15:429
pubmed: 26474974